Solanezumab for the treatment of mild-to-moderate Alzheimers disease

Bruno P. Imbimbo, Simone Ottonello, Vincenza Frisardi, Vincenzo Solfrizzi, Antonio Greco, Davide Seripa, Alberto Pilotto, Francesco Panza

Research output: Contribution to journalArticlepeer-review


Solanezumab (LY2062430) is a humanized monoclonal antibody that binds to the central region of β-amyloid, a peptide believed to play a key role in the pathogenesis of Alzheimers disease (AD). Eli Lilly & Co is developing an intravenous formulation of solanezumab for the treatment of mild-to-moderate AD. Acute and subchronic treatment with solanezumab of transgenic mice attenuated or reversed memory deficits with no effects on incidence or severity of cerebral amyloid angiopathy-associated microhemorrhages, a severe side effect associated with bapineuzumab, another monoclonal antibody. Phase II studies in AD patients have shown a good safety profile with encouraging indications on cerebrospinal and plasma biomarkers. The drug is currently being investigated in Phase III trials. While there is a strong hope that solanezumab may represent the first effective passive vaccine for AD treatment, skepticism still exists on the ability of the drug to slow the rate of deterioration in patients with fully established disease.

Original languageEnglish
Pages (from-to)135-149
Number of pages15
JournalExpert Review of Clinical Immunology
Issue number2
Publication statusPublished - Feb 2012


  • β-amyloid
  • Alzheimers disease
  • bapineuzumab
  • dementia
  • mild cognitive impairment
  • monoclonal antibody
  • passive immunotherapy
  • polyclonal antibody
  • solanezumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Solanezumab for the treatment of mild-to-moderate Alzheimers disease'. Together they form a unique fingerprint.

Cite this